ABSTRACT
Current research was designed to assess the effects of nanocurcumin supplementation on regulatory T (Treg) cells frequency and function in Behçet's disease (BD). In this randomized double-masked, placebo-controlled trial, 36 BD subjects were randomly put into two groups to take one 80 mg nanocurcumin capsule or placebo daily for 8 weeks. Before and after trial, disease activity, Treg cells frequency and expression of related immunologic parameters including forkhead box protein P3 (Foxp3) transcription factor messenger RNA (mRNA) and microRNAs (miRNAs) such as miRNA-25 and miRNA-106b as well as cytokines including transforming growth factor (TGF)-ß and interleukin (IL)-10 were studied. Thirty-two patients (17 in the nanocurcumin and 15 in the placebo groups) completed the trial. Treg cells frequency increased significantly in the nanocurcumin group compared with baseline (P < 0.001) and placebo group (P < 0.001). Moreover, FoxP3, TGF-ß, IL-10, miRNA-25, and miRNA-106b mRNA expression levels increased considerably in the nanocurcumin group compared to baseline (P < 0.001) and placebo group (P < 0.001, P < 0.001, P = 0.025, P = 0.011, and P < 0.001, respectively). Significant increases in serum TGF-ß and IL-10 were seen in nanocurcumin group compared with baseline (P < 0.001) and placebo group (P = 0.001 and P < 0.001, respectively). Significant decrease in disease activity was found in nanocurcumin group compared with placebo group (P = 0.044). Our study provided a promising view for desirable effects of nanocurcumin supplementation in improving immunological parameters and disease activity in BD.
Subject(s)
Behcet Syndrome/diet therapy , Curcumin/therapeutic use , MicroRNAs/genetics , Nanostructures/therapeutic use , T-Lymphocytes, Regulatory/immunology , Adult , Cells, Cultured , Dietary Supplements , Female , Forkhead Transcription Factors/metabolism , Humans , Immunomodulation , Interleukin-10/metabolism , Male , Middle Aged , Transforming Growth Factor beta/metabolismABSTRACT
PURPOSE: To study the ability of pattern reversal visual evoked potentials (VEPs) to detect subclinical visual pathway pathologic assessment in Behcet disease (BD) and correlate VEP results in BD with disease activity and response to corticosteroid treatment. METHODS: This study included 18 patients (36 eyes) with BD without recent ocular manifestations and 20 healthy controls (40 eyes). Clinical history was taken, and clinical examinations were done. Visual evoked potential recordings were performed by an electromyographic evoked machine for patients and controls. Corticosteroids were given to patients with extraocular activity, and VEP was repeated after clinical and laboratory improvement of the manifestations. RESULTS: p100 latency of VEP was prolonged in 8 patients (11 eyes) (44.4% of cases). Mean p100 latency showed statistically significant prolongations in BD group compared with the control group (106.7 ± 8.1 ms vs. 99.6 ± 1.9 ms) with P value < 0.001. There was a positive correlation between p100 latency and the disease activity score (r = 0.8673), whereas there was no correlation between p100 latency and the disease duration (r = 0.00072). Patients treated with corticosteroids showed statistically significant reduction in mean p100 latency after treatment (P < 0.001). CONCLUSIONS: Visual evoked potential may be a valuable tool for detecting subclinical neurologic affection in BD.
Subject(s)
Behcet Syndrome/diagnosis , Behcet Syndrome/physiopathology , Evoked Potentials, Visual/drug effects , Evoked Potentials, Visual/physiology , Adrenal Cortex Hormones/therapeutic use , Adult , Behcet Syndrome/diet therapy , Female , Humans , Male , Middle Aged , Prednisolone/therapeutic use , Visual Pathways/pathologySubject(s)
Bacteria/metabolism , Behcet Syndrome/diet therapy , Butyrates/metabolism , Diet, Vegetarian , Fibrin/metabolism , Fibrinolysis , Gastrointestinal Microbiome , Oxidative Stress , Adult , Behcet Syndrome/blood , Behcet Syndrome/diagnosis , Behcet Syndrome/microbiology , Female , Fermentation , Humans , Lipid Peroxidation , Male , Middle Aged , Oxidation-Reduction , Proof of Concept Study , Reactive Oxygen Species/blood , Time Factors , Treatment OutcomeABSTRACT
We present a 34-year-old man with a two-year history of aphthous stomatitis, who later developed painful, erythematous nodules on his lower extremities. A pathergy test was positive, and the diagnosis of Behçet syndrome (BS) was made. It is important for the dermatologist to recognize the wide variety of cutaneous manifestations of this disorder. A pathergy test is a simple diagnostic tool that may assist in making a diagnosis. Case reports of other unusual skin manifestations in BS also are reviewed.
